Quarterly report [Sections 13 or 15(d)]

Consolidated Balance Sheets

v3.25.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current Assets:    
Cash and cash equivalents $ 26,778 $ 35,469
Restricted cash 393 742
Accounts receivable (net of allowance for credit losses of $38 and $23, respectively) 65,461 58,217
Inventories 50,609 49,914
Derivative instruments 4,071 3,313
Other current assets 6,149 5,463
Total current assets 153,461 153,118
Property and equipment, net 212,624 214,742
Other Assets:    
Right of use operating lease assets, net 19,416 20,553
Intangible assets, net 8,142 4,509
Other assets 8,566 8,516
Total other assets 36,124 33,578
Total Assets 402,209 401,438
Current Liabilities:    
Accounts payable 17,029 20,369
Accrued liabilities 23,819 24,214
Current portion – operating leases 4,968 4,851
Derivative instruments 301 1,177
Other current liabilities 6,999 7,193
Total current liabilities 53,116 57,804
Long-term debt 110,664 92,904
Operating leases, net of current portion 15,641 16,913
Other liabilities 8,868 8,754
Total Liabilities 188,289 176,375
Commitments and Contingencies (Note 7)
Stockholders’ Equity:    
Preferred stock, $0.001 par value; 10,000 shares authorized; Series A: 1,684 shares authorized; no shares issued and outstanding as of March 31, 2025 and December 31, 2024; Series B: 1,581 shares authorized; 927 shares issued and outstanding as of March 31, 2025 and December 31, 2024; liquidation preference of $18,075 as of March 31, 2025 1 1
Common stock value 77 77
Additional paid-in capital 1,045,024 1,044,176
Accumulated other comprehensive income 4,975 4,975
Accumulated deficit (836,157) (824,166)
Total Stockholders’ Equity 213,920 225,063
Total Liabilities and Stockholders’ Equity 402,209 401,438
Non-voting common stock    
Stockholders’ Equity:    
Common stock value